
Immunobiologicals are a reality in current clinical practice and have increasingly gained space in the inflammatory disease scenario, especially in dermatology, with approved drugs for psoriasis, atopic dermatitis, and hidradenitis suppurativa, in addition to many others undergoing study. It is important for dermatologists to have knowledge of the medications approved in Brazil, for the best management of dermatoses, in addition to the fact that they represent hope for improvement in patients with chronic diseases.
Continuing Medical Education, Dermatology, Dermatitis, Atopic, Hidradenitis Suppurativa, Arthritis, psoriatic, Hidradenitis suppurativa, Dermatitis, atopic, RL1-803, Humans, Psoriasis, Brazil
Continuing Medical Education, Dermatology, Dermatitis, Atopic, Hidradenitis Suppurativa, Arthritis, psoriatic, Hidradenitis suppurativa, Dermatitis, atopic, RL1-803, Humans, Psoriasis, Brazil
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 8 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
